Scientists have found that an oral antiviral drug successfully prevents monkeys from dying after an Ebola infection, an advance that may prevent future outbreaks of the deadly virus.

Ebola virus (species Zaire ebolavirus, strain Mayinga) was produced in VeroE6 cells in the BSL4 facility at the Friedrich‐Loeffler Institut (Insel Riems, Greifswald), following approved standard ...

Background Accomplishing infection prevention and control (IPC) in health facilities in Sub-Saharan Africa is challenging. Owing to poor IPC, healthcare workers (HCWs) were frequently infected during ...

The story behind the failure of the world's health organizations to stop the Ebola disaster.

Ebola virus disease kills more than half of people infected. Since the disease is transmitted via close human contact, identifying individuals at the highest risk of developing the disease is possible ...

Ebola virus glycoprotein GP mediates viral infection and serves as the primary target of neutralizing antibodies. Here, we describe a universal Ebola virus vaccine approach using a structure-guided ...

Returning to the starting point of the world’s worst Ebola outbreak reveals how the global community failed the people of Meliandou, Guinea — and the many ways we’re not doing enough to ...

Ebola is a highly pathogenic virus, which in humans reaches a mortality rate above 50%. Due to a lack of laboratories in territories where Ebola viruses are endemic and the limited number of ...

While the world is still dealing with the COVID-19 pandemic and facing unexpected challenges, such as the monkeypox pandemic, an old enemy has reappeared in Africa. On September 20, Uganda reported ...

Additionally, a qualitative reverse-transcriptase polymerase chain reaction (qRT-PCR) assay was specifically developed to detect Ebola strains and was utilized to confirm infection.

Citation: Tshiani Mbaya O, Mukumbayi P and Mulangu S (2021) Review: Insights on Current FDA-Approved Monoclonal Antibodies Against Ebola Virus Infection. Front.

Ebanga ™ (ansuvimab-zykl) is a Zaire ebolavirus glycoprotein (EBOV GP) directed human monoclonal antibody for the treatment of Zaire ebolavirus infection in adult and paediatric patients. Neonates ...